Neither medication should be routinely discontinued—this is an appropriate and guideline-supported combination for hypertension
The combination of lisinopril (ACE inhibitor) and nifedipine (dihydropyridine calcium channel blocker) is explicitly recommended by multiple hypertension guidelines and should generally be continued together. 1, 2, 3
Why This Combination is Recommended
The Canadian Hypertension Education Program guidelines specifically endorse combining a dihydropyridine CCB with an ACE inhibitor as a useful add-on strategy when blood pressure targets are not achieved with monotherapy 1, 2. The 2018 guidelines upgraded this combination from Grade C to Grade A evidence for efficacy 3. This reflects strong clinical trial data showing:
- Additive blood pressure reduction without pharmacokinetic interactions 4
- Superior 24-hour blood pressure control compared to either agent alone 5
- Complementary mechanisms: ACE inhibitors block the renin-angiotensin system while dihydropyridine CCBs provide vasodilation through different pathways 6, 7
When to Consider Discontinuing One Agent
Discontinue Nifedipine if:
- Short-acting nifedipine capsules are being used (not long-acting formulation)—these should be replaced with safer alternatives like felodipine or extended-release nifedipine 8, 9
- Patient develops significant peripheral edema—this is a common CCB side effect that may require switching to monotherapy with the ACE inhibitor
- Blood pressure is well below target and simplification is desired—in this case, continue the lisinopril as it provides additional cardiovascular and renal protection beyond blood pressure lowering 10, 11
Discontinue Lisinopril if:
- Persistent, intolerable dry cough develops that interferes with sleep or quality of life—switch to an angiotensin receptor blocker (ARB) instead 12, 13
- Angioedema occurs—this is an absolute contraindication; discontinue immediately 14
- Hyperkalemia develops (potassium >5.5 mmol/L) despite adjusting other medications 15, 16, 14
- Significant worsening renal function occurs (creatinine increase >100% or to >354 μmol/L [4 mg/dL]) 15, 16
- Pregnancy is confirmed or planned—ACE inhibitors are contraindicated 8, 14
Critical Pitfalls to Avoid
Do not discontinue the ACE inhibitor for mild creatinine elevations. Increases up to 50% above baseline or to 266 μmol/L (3 mg/dL) are acceptable and expected with ACE inhibitor therapy 15, 16. The 2025 kidney dysfunction in heart failure guidelines emphasize that modest creatinine rises during RAAS inhibitor therapy often reflect hemodynamic changes rather than true tubular injury and should not prompt discontinuation 17.
Do not stop either medication abruptly without a clear indication. Both provide cardiovascular protection beyond blood pressure control—lisinopril reduces proteinuria and cardiovascular events 10, 11, while the combination may improve endothelial function more than either agent alone 7.
The Bottom Line
Unless specific adverse effects or contraindications develop, maintain both medications. This combination is evidence-based, guideline-recommended, and provides complementary cardiovascular protection. If simplification is needed due to excellent blood pressure control, prioritize keeping the lisinopril for its broader organ-protective effects, particularly if the patient has diabetes, chronic kidney disease, or cardiovascular disease.